Drug intelligence / Profile preview

B125S5

Development stage: Unknown
Modality: Small Molecules
Administration: Epidural

Overview

B125S5 is a specific combination of 0.125% bupivacaine and 5µg sufentanil in 15mL, designed for epidural analgesia during labor. Bupivacaine, a local anesthetic, primarily functions by blocking voltage-gated sodium channels, thereby inhibiting nerve impulse conduction. Sufentanil, an opioid analgesic, exerts its effects by acting as an agonist at mu-opioid receptors. This combination aims to provide rapid and effective pain relief with minimal side effects during the birthing process.

Other names: 0.125% bupivacaine + 5 μg sufentanil

Targets

NaV (Voltage-gated sodium channels)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on B125S5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on B125S5.

Explore the full profile